GlassScriptPhysician profile
Joseph Samuel Modica
NPI 1023545654
$6,625.53
in general payments reported to CMS, 2019-2025
39 companies · $2,298 in 2025
The $2,298 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $423 · 2023: $1,768 · 2024: $2,136 · 2025: $2,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,781 · Education: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,781.34 |
| Education | $421.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,133.81 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $843.68 | 2022-2025 | Austedo Xr, Ajovy, Austedo |
| Neurocrine Biosciences, INC. | $470.77 | 2022-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $429.57 | 2022-2025 | Nayzilam, Rystiggo, Fintepla |
| Jazz Pharmaceuticals INC. | $402.63 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $372.39 | 2022-2025 | Rytary, Crexont, Lyvispah |
| Collegium Pharmaceutical, INC. | $325.44 | 2023-2025 | Xtampza, Belbuca |
| Lundbeck LLC | $300.93 | 2023-2025 | Vyepti, Rexulti |
| Medtronic, INC. | $242.93 | 2022-2023 | Activa PC |
| Abbott Laboratories | $226.49 | 2022-2025 | Infinity |
| Csl Behring | $167.33 | 2022-2024 | Hizentra |
| Otsuka America Pharmaceutical, INC. | $161.96 | 2023-2025 | Rexulti, Nuedexta |
| Revance Therapeutics, INC. | $140.45 | 2024 | Daxxify |
| Sk Life Science, INC. | $133.37 | 2023-2025 | |
| Boston Scientific Corporation | $132.70 | 2023-2025 | General - Dbs |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $111.96 | 2022-2024 | Nourianz |
| Pfizer INC. | $108.12 | 2024-2025 | |
| Neurelis, INC. | $93.28 | 2023-2025 | Valtoco |
| Averitas Pharma INC. | $84.76 | 2024-2025 | Qutenza |
| Corium, LLC | $64.46 | 2023 | Adlarity |
| Amgen INC. | $62.41 | 2023-2024 | Uplizna, Aimovig |
| Axsome Therapeutics, INC. | $59.60 | 2023-2024 | Sunosi |
| Livanova USA, INC. | $56.24 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Lilly USA, LLC | $53.94 | 2023-2024 | Emgality, Reyvow, Amyvid |
| Grifols USA, LLC | $49.77 | 2025 | Gamunex-C |
| Ge Healthcare | $47.64 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $45.66 | 2022-2025 | Ultomiris |
| Vertex Pharmaceuticals Incorporated | $43.35 | 2024-2025 | |
| Catalyst Pharmaceuticals, INC. | $39.03 | 2024-2025 | |
| Harmony Biosciences LLC | $38.47 | 2023-2024 | Wakix |
| Scilex Pharmaceuticals INC. | $34.50 | 2023-2024 | Ztlido |
| Takeda Pharmaceuticals U.S.A., INC. | $25.60 | 2025 | Hyqvia |
| Eisai INC. | $22.67 | 2024 | |
| Biogen, INC. | $21.55 | 2025 | Spinraza |
| Acorda Therapeutics, INC | $21.00 | 2023 | Inbrija, Ampyra |
| Merz Pharmaceuticals, LLC | $20.73 | 2025 | Xeomin, Inbrija |
| Azurity Pharmaceuticals, INC. | $19.51 | 2025 | Zonisade |
| Tanabe Pharma America, INC. | $16.83 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$386,657.15 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Modica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.